[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639355":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":26,"centralContacts":30,"locations":35,"responsibleParty":53,"collaborators":20,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":20,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":20,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":38,"whyStopped":20,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Glaukos Corporation","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Epioxa™ HD\u002FEpioxa™ and UV-A Irradiation","EXPERIMENTAL","Epioxa™ HD\u002FEpioxa™ and UV-A Irradiation using the O2n™ System and Supplemental Oxygen using the Boost Goggles®",[13,14],"Drug: Riboflavin Ophthalmic Solutions","Device: UV-A Irradiation System",[16,21],{"type":17,"name":18,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Riboflavin Ophthalmic Solutions",[9],null,{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":20},"DEVICE","UV-A Irradiation System","O2n UV-A Irradiation System",[9],[27],{"name":28,"affiliation":5,"role":29},"Study Director","STUDY_DIRECTOR",[31],{"name":28,"role":32,"phone":33,"phoneExt":20,"email":34},"CONTACT","949-739-8749","ClinicalResearch@glaukos.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Glaukos Investigative Site","RECRUITING","Westerville","Ohio","43082","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-82.92907,40.12617,{"lat":48,"lon":47},[51],{"name":52,"role":32,"phone":33,"phoneExt":20,"email":34},"Study Director, MD",{"type":54,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100639355","phase-4-evaluate-the-safety-and-feasibility-of-same-day-bilateral-epithelium-on-corneal-cross-linking-for-keratoconus-100639355",false,"NCT07629557","Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus","Single-arm, Multi-center Study to Evaluate the Safety and Feasibility of Bilateral Epithelium-on Corneal Collagen Cross-linking With Epioxa™ HD\u002FEpioxa™ and UV-A Irradiation Using the O2n™ System and Supplemental Oxygen Using the Boost Goggles® in Subjects With Keratoconus","Inclusion Criteria:\n\n* Provide written informed consent\n* Willing and able to comply with study instructions and follow-up visits\n* Diagnosis of keratoconus in each eye\n\nExclusion Criteria:\n\n* Known allergy or sensitivity to study medications\n* History of corneal disease\n* Prior corneal cross-linking in either eye\n* Pregnant, nursing, or planning pregnancy during the study period\n* Participated in other investigational drug or device trial within 30 days of the study","ALL","13 Years",{"count":65,"type":66},15,"ESTIMATED","INTERVENTIONAL",[69],"PHASE4","Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.",[72],"Keratoconus",[72,74],"Corneal Cross-linking","2026-06-01",{"date":77,"type":78},"2026-06-05","ACTUAL",{"date":80,"type":78},"2026-05-11",{"date":82,"type":66},"2027-09",{"name":5,"class":6},1]